Coeptis Therapeutics, Inc.
NASDAQ:COEP · NASDAQ Capital Market
+$0.73 today
Vol 0.13M · Avg 0.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-69.1%
avg -312.9%
ROIC
-71.7%
avg -103.9%
ROA
-60.1%
avg 124.4%
Analysis
ROA is currently the strongest return metric at -60.1% versus its period average of 124.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David Mehalick | Co-Founder, Chairman of the Board, Chief Executive Officer & President | $597,000.00 | — | 57 | $330,192.00 | 9.40% |
Daniel Alexander Yerace | Co-Founder, Vice President of Operations & Director | $452,000.00 | — | 43 | $70,531.00 | 2.01% |
Brian Cogley | Chief Financial Officer | $310,385.00 | — | 39 | $22,500.00 | 0.64% |
Christine Elise Sheehy | Co-Founder, VP of Compliance & Corporate Secretary | $75,000.00 | — | 58 | $64,031.00 | 1.82% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +58.3% (7yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +58.3% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$204.42M
Century Therapeutics, Inc.
NASDAQ:IPSC
$198.24M
Equillium, Inc.
NASDAQ:EQ
$108.34M
OS Therapies Incorporated
AMEX:OSTX
$85.96M
Cue Biopharma, Inc.
NASDAQ:CUE
$74.79M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$68.62M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$65.00M
Telomir Pharmaceuticals, Inc. Common Stock
TELO
$48.82M
Senti Biosciences, Inc.
SNTI
$24.50M
Medicus Pharma Ltd. Common Stock
MDCX
$10.08M
Who manages COEP?
Coeptis Therapeutics, Inc. (COEP) lists 4 active executives. The top listed executive is Daniel Alexander Yerace, Co-Founder, Vice President of Operations & Director.
Are COEP insiders buying or selling?
Recent insider activity shows net buying of $42.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.